Featured Research

from universities, journals, and other organizations

Early Trial Of New Multi-kinase Inhibitor Shows Impressive Activity In Thyroid Cancer

Date:
October 27, 2008
Source:
ECCO-the European CanCer Organisation
Summary:
Preliminary trials of a new multi-kinase inhibitor have indicated it has impressive tumor shrinkage activity in patients with a difficult to treat type of thyroid cancer. The results have put the drug's development on a fast track, prompting the accelerated initiation of a large phase III trial.

Preliminary trials of a new multi-kinase inhibitor have indicated it has impressive tumour shrinkage activity in patients with a difficult to treat type of thyroid cancer. The results have put the drug's development on a fast track, prompting the accelerated initiation of a large phase III trial.

The compound, XL184, targets cell growth and migration, as well as blood vessel growth (angiogenesis), through inhibition of MET kinase, VEGFR and RET kinase.

In a study presented October 23 at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva, 84 patients with a variety of advanced tumours that were not amenable to standard therapy were administered XL184 for either the first five days of a 14-day cycle or daily throughout the cycle. The group included 36 patients with advanced medullary thyroid cancer, for which no treatment is known to work. Response to the drug was assessed at 28 days and subsequently every eight weeks.

The impact on tumour shrinkage was particularly notable in the medullary thyroid cancer patients, where the overall disease control rate – the percentage of patients with either a partial response to the drug or prolonged stable disease for more than three months – was 84% in the 25 patients who have been followed for at least three months, said the study's presenter, Professor Steven Sherman, chair of the Department of Endocrine Neoplasia and Hormonal Disorders at M.D. Anderson Cancer Center in Houston (Texas, USA).

"Partial response, where tumours shrink by at least 30%, was achieved in 55% of the 22 patients with measurable disease who have been followed for at least three months. Most of the others experienced prolonged stable disease beyond three months, and for most of these patients there was actually tumour shrinkage. That is an impressive result for an early trial in this type of cancer," Professor Sherman said.

Three of the medullary thyroid cancer patients had unmeasurable disease. Tumour biomarkers such as plasma calcitonin and CEA dropped significantly after therapy in most of the patients.

Of the 84 patients, including patients with diverse cancers, disease stabilisation for at least three months was seen in 28 cases. In sixteen of those cases, the disease was stable for six months or more, the study found. The most common adverse effects of the drug included diarrhoea (24%), nausea (18%) and fatigue (15%).

In a preclinical study presented on Friday at the conference, XL184 showed encouraging results in boosting sensitivity to erlotinib and gefitinib in drug-resistant lung cancer. Gefitinib and erlotinib belong to a class of targeted drugs that zero in on the epidermal growth factor receptor (EGFR) gene, which is mutated in many non-small cell lung cancers. MET kinase, which is inhibited by XL184, is implicated in the resistance to EGFR kinase inhibitors.

In the study, mice were grafted with human EGFR mutant and MET amplified non-small cell lung cancer tumours that were made resistant to gefitinib.

"Neither agent was effective alone, but tumour regression occurred in all animals when they were treated with a combination of erlotinib and XL184," said the mouse study's leader, Professor Pasi Janne, an assistant professor of medicine at Harvard University Medical School in Boston (Massachusetts, USA).

A clinical trial has now been initiated, testing XL184 with or without erlotinib in non-small cell lung cancer patients who have developed resistance to erlotinib. The phase III trial of XL184 in medullary thyroid cancer patients involves using the drug alone. XL184 is also being studied in glioblastoma.


Story Source:

The above story is based on materials provided by ECCO-the European CanCer Organisation. Note: Materials may be edited for content and length.


Cite This Page:

ECCO-the European CanCer Organisation. "Early Trial Of New Multi-kinase Inhibitor Shows Impressive Activity In Thyroid Cancer." ScienceDaily. ScienceDaily, 27 October 2008. <www.sciencedaily.com/releases/2008/10/081023100858.htm>.
ECCO-the European CanCer Organisation. (2008, October 27). Early Trial Of New Multi-kinase Inhibitor Shows Impressive Activity In Thyroid Cancer. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2008/10/081023100858.htm
ECCO-the European CanCer Organisation. "Early Trial Of New Multi-kinase Inhibitor Shows Impressive Activity In Thyroid Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/10/081023100858.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins